Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lycia Therapeutics, Inc. announced that it has received $70.055062 million in funding from a group of investors

09/16/2021 EDT

On September 16, 2021, Lycia Therapeutics, Inc. closed the transaction. The company has raised $55,062 in its final tranche bringing total proceeds to $70,055,062 from 11 investors.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
07:39aMizuho Securities Adjusts Eli Lilly and Co.'s Price Target to $272 From $279, Reiterate..
MT
10/26Eli Lilly Reports Higher Third-Quarter Results, Raises 2021 Forecast to Reflect Increas..
MT
10/26GLOBAL MARKETS LIVE : Michelin, Facebook, UBS, Tesla, Volvo...
10/26Eli Lilly Intends to Complete US Marketing Application Submission for Alzheimer's Drug ..
MT
10/26Eli Lilly Alzheimer's Programs Head in Different Directions
DJ
10/26Health Care Stocks Edge Higher Premarket Tuesday
MT
10/26Eli Lilly, Pfizer Halt Program for Osteoarthritis Pain Drug
MT
10/26Lilly kicks off application for Alzheimer's drug U.S. approval, ups outlook
RE
10/26WALL STREET STOCK EXCHANGE : Are companies fooling themselves on inflation?
10/26Lilly Cuts Income Targets, Lifts Sales Forecast For FY21
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 453 M - -
Net income 2021 6 145 M - -
Net Debt 2021 11 808 M - -
P/E ratio 2021 38,4x
Yield 2021 1,34%
Capitalization 225 B 225 B -
EV / Sales 2021 8,63x
EV / Sales 2022 8,39x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 248,44 $
Average target price 270,05 $
Spread / Average Target 8,70%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.15%225 231
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
MERCK & CO., INC.0.55%208 206